Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WXNKG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
JBH492
|
|||||
| Synonyms |
JBH492; JBH-492
Click to Show/Hide
|
|||||
| Organization |
Novartis (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
121G12
|
Antibody Info | ||||
| Antigen Name |
C-C chemokine receptor type 7 (CCR7)
|
Antigen Info | ||||
| Payload Name |
DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Chronic lymphocytic leukemia |
1 Trials
|
||||||||
| Unspecific non-hodgkin lymphoma |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | stable disease (SD) |
8%
|
|||
| Patients Enrolled |
Inclusion criteria for CLL patients require a confirmed diagnosis, while NHL patients must have a histologically confirmed diagnosis and be willing to undergo biopsies. Exclusion criteria apply to both groups, covering hypersensitivity to ADCs or mAbs, prior DM1/DM4 ADC treatment, corneal disorders, CNS involvement (unless treated), cardiac impairment, HIV, and active HBV/HCV (with controlled cases under antivirals eligible). Additional criteria may apply.
Click to Show/Hide
|
||||
| Administration Dosage |
Five dose levels of JBH492 monotherapy ranging from 0.4 to 3.6 mg/kg (intravenous administration every 3 weeks [q3W]) were tested with 3 - 7 pts enrolled per dose level.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04240704 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | ||||
| Primary Endpoint |
The study evaluates the incidence and severity of dose-limiting toxicities (DLTs), adverse events (AEs), and serious adverse events (SAEs) over 32 months, with DLTs defined as protocol-specified adverse events during the first treatment cycle. It also measures treatment interruptions, dose reductions, and dose intensity, where relative dose intensity is calculated for subjects with non-zero exposure.
Click to Show/Hide
|
||||
| Other Endpoint |
Key efficacy outcomes include overall response rate (ORR), best overall response (BOR), duration of response (DOR), and progression-free survival (PFS) over 32 months. Pharmacokinetic (PK) parameters cover AUClast, AUCinf, AUCtau, Cmax, Cmin, Tmax, and T1/2 for four analytes, alongside anti-JBH492 antibody incidence.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Partial Response (PR) |
16%
|
|||
| Patients Enrolled |
Inclusion criteria for CLL patients require a confirmed diagnosis, while NHL patients must have a histologically confirmed diagnosis and be willing to undergo biopsies. Exclusion criteria apply to both groups, covering hypersensitivity to ADCs or mAbs, prior DM1/DM4 ADC treatment, corneal disorders, CNS involvement (unless treated), cardiac impairment, HIV, and active HBV/HCV (with controlled cases under antivirals eligible). Additional criteria may apply.
Click to Show/Hide
|
||||
| Administration Dosage |
Five dose levels of JBH492 monotherapy ranging from 0.4 to 3.6 mg/kg (intravenous administration every 3 weeks [q3W]) were tested with 3 - 7 pts enrolled per dose level.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04240704 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | ||||
| Primary Endpoint |
The study evaluates the incidence and severity of dose-limiting toxicities (DLTs), adverse events (AEs), and serious adverse events (SAEs) over 32 months, with DLTs defined as protocol-specified adverse events during the first treatment cycle. It also measures treatment interruptions, dose reductions, and dose intensity, where relative dose intensity is calculated for subjects with non-zero exposure.
Click to Show/Hide
|
||||
| Other Endpoint |
Key efficacy outcomes include overall response rate (ORR), best overall response (BOR), duration of response (DOR), and progression-free survival (PFS) over 32 months. Pharmacokinetic (PK) parameters cover AUClast, AUCinf, AUCtau, Cmax, Cmin, Tmax, and T1/2 for four analytes, alongside anti-JBH492 antibody incidence.
|
||||